Enochian Biosciences, Inc. (ENOB)
Stock Price:
$3.36 USD
0.06 (1.82%)
Updated Oct 23, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
156.70M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-11.42M |
| Shares Out |
46.64M |
| EPS (ttm) |
-0.25 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 23, 2020 |
| Last Price |
$3.36 |
| Previous Close |
$3.30 |
| Change ($) |
0.06 |
| Change (%) |
1.82% |
| Day's Open |
3.30 |
| Day's Range |
3.30 - 3.50 |
| Day's Volume |
28,232 |
| 52-Week Range |
1.95 - 13.43 |
More Stats
| Market Cap |
156.70M |
| Enterprise Value |
155.59M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
46.64M |
| Float |
3.81M |
| EPS (basic) |
-0.25 |
| EPS (diluted) |
-0.25 |
| FCF / Share |
-0.22 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
1.06M |
| Short Ratio |
8.61 |
| Short % of Float |
27.87% |
| Beta |
0.43 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
0.94 |
| Revenue |
n/a |
| Operating Income |
-11.92M |
| Net Income |
-11.42M |
| Free Cash Flow |
-10.27M |
| Net Cash |
1.11M |
| Net Cash / Share |
0.02 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-4.16% |
| ROE |
-6.73% |
| ROIC |
-171.50% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (0)
| Buy |
0 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
*No analysts have provided price targets for this stock.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2020 | 2019 | 2018 | 2017 |
|---|
| Revenue | - | - | - | - |
| Operating Income | -11.92 | -10.99 | -5.33 | -2.40 |
| Net Income | -11.42 | -18.02 | -6.31 | -2.14 |
| Shares Outstanding | 46.33 | 37.55 | 21.94 | 12.27 |
| Earnings Per Share | -0.25 | -0.48 | -0.29 | -0.17 |
| Operating Cash Flow | -10.46 | -8.51 | -4.34 | -1.18 |
| Capital Expenditures | 0.18 | -0.72 | -0.03 | - |
| Free Cash Flow | -10.27 | -9.22 | -4.37 | -1.18 |
| Cash & Equivalents | 8.70 | 12.28 | 15.60 | 3.94 |
| Total Debt | 7.58 | - | - | 2.09 |
| Net Cash / Debt | 1.11 | 12.28 | 15.60 | 1.85 |
| Assets | 178 | 180 | 183 | 4.52 |
| Liabilities | 11.83 | 6.78 | 23.76 | 2.99 |
| Book Value | 166 | 173 | 159 | 1.53 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Enochian Biosciences, Inc. |
| Country |
United States |
| Employees |
10 |
Stock Information
| Ticker Symbol |
ENOB |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: ENOB |
Description
Enochian Biosciences, a pre-clinical stage biotechnology company, focuses on development of human therapeutics for infectious diseases and cancers. The company's lead candidate include ENOB-HV-01 for autologous HIV curative treatment. Its pipeline development products consist of ENOB-HV-11, a preventive HIV vaccine; and ENOB-HV-12, a therapeutic HIV vaccine. The company's pipeline development products also include ENOB-HB-01, a coopting Hepatitis B polymerase; ENOB-DC-01, an off-the-shelf DC vaccine pulsed with MCV lysate; ENOB-DC-11 innovative DC vaccine for multiple solid tumors; and ENOB-DC-21, a non-specific vaccine for intratumoral injection. The company has strategic partnerships with The Scripps Institute, Fred Hutchinson Cancer Center, and The Hepatitis B Foundation and Baruch S. Blumberg Institute. Enochian Biosciences, Inc. is headquartered in Los Angeles, California.